Please use this identifier to cite or link to this item:
Title: Status of PCSK9 Monoclonal Antibodies in Australia.
Austin Authors: Scherer, Daniel J;Nelson, Adam J;O'Brien, Richard C ;Kostner, Karam M;Hare, David L ;Colquhoun, David M;Barter, Philip J;Aylward, Philip;Nicholls, Stephen J;Watts, Gerald F
Affiliation: Department of Medicine, Monash University, Melbourne, Vic, Australia
School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
Flinders University and Medical Centre, Adelaide, SA, Australia
Department of Cardiology, Mater Hospital, University of Queensland, Brisbane, Qld, Australia
School of Medicine, Faculty of Medicine and Health Sciences, University of Western Australia, Perth, Australia
Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Perth, Australia
School of Medicine, University of Queensland, Brisbane, Qld, Australia
Wesley Medical Centre, Wesley Hospital and Greenslopes Private Hospital, Brisbane, Qld, Australia
Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Vic, Australia
Department of Cardiology, Austin Health, Heidelberg, Victoria, Australia
Austin Health Clinical School, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia
South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia
University of Adelaide, Adelaide, SA, Australia
Issue Date: Oct-2019 2019-05-08
Publication information: Heart, Lung & Circulation 2019; 28(10): 1571-1579
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.
DOI: 10.1016/j.hlc.2019.04.014
PubMed URL: 31104887
Type: Journal Article
Subjects: Atherosclerosis
Cardiovascular risk
PCSK9 inhibitors
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.